NCT05317767View on ClinicalTrials.gov

The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.

PHASE3CompletedINTERVENTIONAL

Enrollment

600

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

July 5, 2020

Study Completion Date

September 14, 2020

Conditions

Influenza

Interventions

BIOLOGICAL

Flu-M [Inactivated split influenza vaccine]

solution for intramuscular injection, 0.5 ml

BIOLOGICAL

Inactivated Split Influenza Vaccine

solution for intramuscular injection, 0.5 ml

Trial Locations (2)

Unknown

Perm State Medical University named after Academician E. A. Wagner, Perm

"LLC Meditsinskie Tehnologii", Saint Petersburg

All Listed Sponsors

lead

St. Petersburg Research Institute of Vaccines and Sera

OTHER_GOV

NCT05317767 - The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years. | Biotech Hunter | Biotech Hunter